Overweight and ObesityTIMEXNCT05153252
Timing Intervention of Morning Versus Evening Exercise
A study testing Morning Exercise and Evening Exercise in people with Overweight and Obesity, run by University of Colorado, Denver at 1 site in United States.
Trial summary
The investigators are doing this study to learn more about how exercising at different times of the day (morning versus evening) affects body weight, sleep, eating patterns, and other factors. Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Overweight and Obesity
- What is being tested?
- Morning Exercise and Evening Exercise
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 128 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Dec 2021to 31 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Female or Male
- Age 18-55 years
- Body Mass Index 25-40 kg/m2
- Physically inactive: defined as self-reporting <150 minutes per week of physical activity at moderate intensity or greater on a regular basis over the past 3 months.
- No self-report of acute or chronic disease (cardiovascular disease (CVD), diabetes, gastrointestinal disorders and orthopedic problems in particular)
- No plans to relocate within the next 15 months.
Show all 20Show fewer
- No plans for extended travel (> 2 weeks) within the next 13 months
- Live or work within 30 minutes of the Anschutz Health \& Wellness Center (AHWC) (exceptions may be made at the discretion of the Study PI on a case-by-case basis for highly motivated subjects).
- Capable and willing to give informed consent, understand exclusion criteria, accept the randomized group assignment, and complete outcome measures.
- No contraindications to exercise or limitations on ability to be physically active.
- Willing to be randomized to either AM or PM exercise and complete 4 exercise sessions per week.
- Own a smart phone and willing to download and use text messaging for meal intake and other related assessments.
- Willing and able to wear activity/sleep monitor for 7-14 consecutive days.
- Willing not to enroll in any other formal weight loss or physical activity programs over the next 13 months.
- Fully vaccinated, or willing to be fully vaccinated, against COVID-19 prior to study enrollment (fully vaccinated is defined as at least 2 weeks post final vaccine dose).
- Have a primary care physician (or are willing to establish care with a primary care physician prior to study enrollment) to address medical issues which may arise during screening or study procedures/interventions.
- For Females
- Not currently pregnant or lactating
- Not pregnant within the past 6 months
- Not planning to become pregnant in the next 15 months; sexually active women of childbearing potential may be enrolled if they have had a tubal ligation or use a reliable means of contraception
Who cannot join
- Diastolic blood pressure > 100 mm HG or systolic blood pressure > 160 mm HG.
- Resting heart rate >100
- Diabetes (fasting glucose ≥126 mg/dL or Hemoglobin A1C ≥6.5%)
- Undiagnosed hypo- or hyper-thyroidism (Thyroid Stimulating Hormone (TSH) outside of the normal range) or history of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable.
- Hematocrit, white blood cell count or platelets significantly outside the normal reference range.
- Clinically significant abnormalities in hematocrit, white blood cell count or platelets.
Show all 29Show fewer
- Triglycerides > 400 mg/dL
- (Low Density Lipids) LDL cholesterol >200 mg/dL
- Abnormal resting electrocardiogram (ECG): serious arrhythmias, including multifocal premature ventricular contractions (PVC's), frequent PVC's (defined as 10 or more per min), ventricular tachycardia (defined as runs of 3 or more successive PVC's), or sustained atrial tachyarrhythmia; 2nd or 3rd degree A-V block, QTc interval > 480 msec or other significant conduction defects.
- Presence or history of any metabolic or chronic health problems which would affect appetite, food intake, energy metabolism, or ability to optimally participate in the exercise component including: CVD, peripheral vascular disease, cerebrovascular disease, significant cardiac arrhythmias or cardiac valve disease, diabetes, uncontrolled hyper- or hypothyroidism, uncontrolled hypertension, cancer (within the last 5 years, except skin cancer or other cancers considered cured with excellent prognosis), HIV infection, significant gastrointestinal disorders (described below), significant pulmonary disorders (described below), significant renal, musculoskeletal, neurologic, hematologic, or psychiatric disease.
- Significant gastrointestinal disorders including: Crohn's disease, Ulcerative Colitis, chronic diarrhea, or active gallbladder disease.
- Significant pulmonary disorders including: chronic obstructive pulmonary disease (COPD), interstitial lung disease, cystic fibrosis, or uncontrolled asthma.
- Symptoms suggestive of CVD: chest pain, shortness of breath at rest or with mild exertion, syncope.
- Regular use of prescription or over-the-counter medications known to significantly impact appetite, weight, sleep, or energy metabolism (e.g., appetite suppressants, lithium, stimulants, anti-psychotics, tricyclic antidepressants)
- Use of medications that would impact ability to achieve age-predicted maximum heart rate (e.g. beta blockers, cardio-selective calcium channel blockers).
- Regular use of systemic steroids (other than Oral Contraceptive Pills)
- Regular use of obesity pharmacotherapeutic agents within the last 6 months.
- Previous obesity treatment with surgery or weight loss device, except: (1) liposuction and/or abdominoplasty if performed > 1 year before screening, (2) lap banding if the band has been removed > 1 year before screening, (3) intragastric balloon if the balloon has been removed > 1 year before screening (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed > 1 year before screening or 5) AspireAssist or other endoscopically placed weight loss device if the device has been removed > 1 year before screening.
- Current alcohol or substance abuse
- Nicotine use (past 6 months)
- History of clinically diagnosed eating disorders including anorexia nervosa, bulimia, binge eating disorder. Score >20 on the Eating Attitudes Test (EATS-26) or pattern of response on the Questionnaire on Eating and Weight Patterns (QEWP-5) suggestive of possible binge eating disorder or bulimia will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.
- Current severe depression or history of severe depression within the previous year, based on Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria for Major Depressive Episode. Score > 18 on Beck Depression Inventory (BDI) will require further assessment by the Study MD to determine if it is appropriate for the subject to participate in the study.
- History of other significant psychiatric illness (e.g. psychosis, schizophrenia, mania, bipolar disorder) which in the opinion of the Study MD would interfere with ability to adhere to dietary or exercise interventions.
- Night-time shiftwork, rotating work, irregular sleep/wake patterns or other scheduling constraints which may hinder ability to consistently exercise at specific times of the day.
- Urinary incontinence or retention (as per PI discretion based on whether degree of incontinence/retention may impact doubly labeled water measures).
- Weight loss >5% in past 3 months.
- Weight gain >10% in past 3 months requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study.
- Weight loss of >50 lbs in past 3 years for any reason except post-partum weight loss requires assessment by PI to determine reason for weight gain and if it is appropriate for the subject to participate in the study.
- Currently participating in or planning to participate in any formal weight loss, dietary modification, or physical activity/exercise programs or clinical trials.
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045
About this study
Official title: Does When You Exercise Matter? A Randomized Trial Comparing the Effect of Morning Versus Evening Aerobic Exercise on Weight Loss and Compensatory Behaviors
The investigators are doing this study to learn more about how exercising at different times of the day (morning versus evening) affects body weight, sleep, eating patterns, and other factors.
Read the detailed description
Does the time of day that exercise is performed matter for weight loss? The objective of this proposal is to examine the impact of an equivalent dose of morning vs. evening aerobic exercise on change in body weight, energy intake (EI) and components of energy expenditure (EE) in adults with overweight or obesity. Nearly two-thirds of US adults who attempt to lose weight report engaging in exercise as a primary strategy for weight loss. However, weight loss from exercise alone is often substantially less than predicted based on calories burned in exercise. This is due to compensatory changes that occur in response to exercise initiation (e.g. increases in EI and decreases in non-exercise EE) that limit the energy deficit produced by exercise. Thus, strategies that reduce the compensatory response to exercise could enhance the weight loss efficacy of exercise. It is possible that exercise time of day could impact compensatory behaviors and weight loss, however, there have been no adequately powered, prospective, randomized studies comparing weight loss induced by morning vs. evening exercise. The study design is a 7-month supervised trial in which adults with overweight or obesity will be randomized to supervised aerobic exercise (2000 kcal/wk) performed either in the morning (AM-Ex, 6-10 AM) or the evening (PM-Ex, 3-7 PM). The supervised exercise phase will be followed by a 6-month maintenance phase during which participants continue to exercise at the target of 2000 kcal/week during the randomized AM or PM exercise windows, but exercise is no longer supervised. Aim 1 will compare the effects of AM-Ex vs. PM-Ex on changes in body weight and body composition with the primary study outcome of weight change at 7-months. Aim 2 will compare the effects of AM-Ex vs PM-Ex on changes in EI and appetite. Aim 3 will compare the effects of AM-Ex vs PM-Ex on changes in EE, non-exercise physical activity and sedentary time. Exploratory Aim 4 will compare the effects of AM-Ex vs PM-Ex on changes in meal and sleep timing. This approach is rigorous and innovative as the exercise energy deficit will be matched between groups, exercise will be prescribed based on EE, and free-living total daily energy expenditure (TDEE) and EI will be assessed objectively (using doubly-labeled water). This study is significant as it could provide important insight on how the timing of exercise impacts weight loss and compensatory behaviors.
- Conditions
- Overweight and Obesity
- Being tested
- Morning Exercise, Evening Exercise
- Keywords
- Overweight, Obesity, Exercise
- Medical subject headings
- Overweight, Obesity, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Morning ExerciseBehavioural
Also called AM Exercise, AM-EX
Morning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM.
Evening ExerciseBehavioural
Also called PM Exercise, PM-EX
PM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM.
| Study group | Role | What they receive |
|---|---|---|
| Morning Exercise (AM) | Experimental | Participants in this group will be prescribed morning aerobic exercise. Receives: Behavioral: Morning Exercise |
| Evening Exercise (PM) | Experimental | Participants in this group will be prescribed evening aerobic exercise. Receives: Behavioral: Evening Exercise |
What is being measured
The primary outcome is the main question the study is designed to answer.
Weight Change (kg)
Body weight will be measured using a digital scale at baseline, 3.5, 7, and 13 months. The primary outcome will be change in weight from baseline to 7 months.
Measured: Baseline (0) - 13 Months
Secondary outcomes (9)
Fat Mass
Fat mass will assessed using Dual-Energy X-Ray Absorptiometry (DXA) at baseline, 7, and 13 months.
Measured: Baseline (0) - 13 Months
Lean Mass
Lean Mass will assessed using Dual-Energy X-Ray Absorptiometry (DXA) at baseline, 7, and 13 months.
Measured: Baseline (0) - 13 Months
Energy Intake
Energy Intake (EI) will be assessed using the Doubly Labeled Water (DLW) Intake-Balance Method at baseline and 7
Measured: Baseline (0) - 7 Months
Total Daily Energy Expenditure
Total Daily Energy Expenditure (TDEE) will be assessed using doubly labeled water (DLW) at baseline and 7 months
Measured: Baseline (0) - 7 Months
Hunger and Satiety
Assessed with visual analog scale (0-100 range). Higher scores indicate higher levels of hunger (worse outcome) and satiety (better outcome). Measured at baseline, 3.5, 7, and 13 months
Measured: Baseline (0) - 13 Months
Food Cravings
Assessed with 2 questionnaires at baseline, 3.5, 7, and 13 months: Food Cravings Questionnaire Trait-reduced (FCQ-T-r) and and FCI-II. Higher scores indicate greater cravings (worse outcome). Food Cravings Questionnaire-Trait-reduced (FCQ-T-r) is a Likert Scale using scoring associated with it Strongly disagree = 1, Disagree = 2, Neither agree nor disagree = 3, Agree= 4, Strongly agree = 5. The FCI-II is scored on a Likert scale from 1-5, with 1 being "Never," 5 being "Always/Almost every day." It has 4 subscales: High Fats, Sweets, Carbohydrates/Starches, and Fast-Food Fats. The score for each subscale is obtained by averaging the responses to the items listed for the subscale. The total score is obtained by averaging the responses to all 28 items.
Measured: Baseline (0) - 13 Months
Aspects of Eating Behavior
Measured via Three-Factor Eating Questionnaire at baseline, 3.5, 7, and 13 months. This assessment is designed to measure 3 dimensions of human eating behavior: cognitive restraint of eating (Factor I - 20 items), disinhibition (Factor II - 16 items), and hunger (Factor III - 15 items). The minimum score for factors I-II-III is therefore 0-0-0, and maximum possible score is 20-16-15. Part I includes items 1-36 and are rated either 1-True or 0-False. Part II includes items 37-51 and is rated on a 4-point scale with the exception of item 50, which is rated on a 6-point scale.
Measured: Baseline (0) - 13 Months
Non-Exercise Physical Activity (NEPA)
NEPA will be measured with the ActivPAL device at baseline, 3.5, 7, and 13 months
Measured: Baseline (0) - 13 Months
Sedentary Time
Sedentary Time will be measured with the ActivPAL device at baseline, 3.5, 7, and 13 months
Measured: Baseline (0) - 13 Months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2021
- Study start7 Dec 2021
- Primary completion31 Mar 2027 (estimated)
- Study completion31 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overweight and ObesityStudies of the same condition, open and under way.
- More trials run by University of Colorado, DenverThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Colorado, Denver
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Vicki Catenacci, Principal investigator, University of Colorado, Denver
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05153252
- Sponsor's protocol ID
- 21-3094
- Other IDs
- 1R01DK126814-01A1
- Acronym
- TIMEX
- Status last verified
- Jul 2026
- First submitted
- 23 Nov 2021
- Last updated
- 30 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does When You Exercise Matter? A Randomized Trial Comparing the Effect of Morning Versus Evening Aerobic Exercise on Weight Loss and Compensatory Behaviors
- ClinicalTrials.gov ID
- NCT05153252
- Acronym / sponsor ID
- TIMEX / 21-3094
- Conditions
- Overweight and Obesity
- Keywords
- Overweight, Obesity, Exercise
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 128 participants (estimated)
- Lead sponsor
- University of Colorado, DenverUniversity, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- 7 Dec 2021 (actual)
- Primary completion
- 31 Mar 2027 (estimated)
- Study completion
- 31 Mar 2027 (estimated)
- First posted
- 10 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators are doing this study to learn more about how exercising at different times of the day (morning versus evening) affects body weight, sleep, eating patterns, and other factors.
Detailed description
Does the time of day that exercise is performed matter for weight loss? The objective of this proposal is to examine the impact of an equivalent dose of morning vs. evening aerobic exercise on change in body weight, energy intake (EI) and components of energy expenditure (EE) in adults with overweight or obesity. Nearly two-thirds of US adults who attempt to lose weight report engaging in exercise as a primary strategy for weight loss. However, weight loss from exercise alone is often substantially less than predicted based on calories burned in exercise. This is due to compensatory changes that occur in response to exercise initiation (e.g. increases in EI and decreases in non-exercise EE) that limit the energy deficit produced by exercise. Thus, strategies that reduce the compensatory response to exercise could enhance the weight loss efficacy of exercise. It is possible that exercise time of day could impact compensatory behaviors and weight loss, however, there have been no adequately powered, prospective, randomized studies comparing weight loss induced by morning vs. evening exercise. The study design is a 7-month supervised trial in which adults with overweight or obesity will be randomized to supervised aerobic exercise (2000 kcal/wk) performed either in the morning (AM-Ex, 6-10 AM) or the evening (PM-Ex, 3-7 PM). The supervised exercise phase will be followed by a 6-month maintenance phase during which participants continue to exercise at the target of 2000 kcal/week during the randomized AM or PM exercise windows, but exercise is no longer supervised. Aim 1 will compare the effects of AM-Ex vs. PM-Ex on changes in body weight and body composition with the primary study outcome of weight change at 7-months. Aim 2 will compare the effects of AM-Ex vs PM-Ex on changes in EI and appetite. Aim 3 will compare the effects of AM-Ex vs PM-Ex on changes in EE, non-exercise physical activity and sedentary time. Exploratory Aim 4 will compare the effects of AM-Ex vs PM-Ex on changes in meal and sleep timing. This approach is rigorous and innovative as the exercise energy deficit will be matched between groups, exercise will be prescribed based on EE, and free-living total daily energy expenditure (TDEE) and EI will be assessed objectively (using doubly-labeled water). This study is significant as it could provide important insight on how the timing of exercise impacts weight loss and compensatory behaviors.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Morning Exercise (AM) | Experimental | Behavioral: Morning ExerciseParticipants in this group will be prescribed morning aerobic exercise. |
| Evening Exercise (PM) | Experimental | Behavioral: Evening ExerciseParticipants in this group will be prescribed evening aerobic exercise. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (20 listed)
- Female or Male
- Age 18-55 years
- Body Mass Index 25-40 kg/m2
- Physically inactive: defined as self-reporting <150 minutes per week of physical activity at moderate intensity or greater on a regular basis over the past 3 months.
- No self-report of acute or chronic disease (cardiovascular disease (CVD), diabetes, gastrointestinal disorders and orthopedic problems in particular)
Key exclusion criteria (29 listed)
- Diastolic blood pressure > 100 mm HG or systolic blood pressure > 160 mm HG.
- Resting heart rate >100
- Diabetes (fasting glucose ≥126 mg/dL or Hemoglobin A1C ≥6.5%)
- Undiagnosed hypo- or hyper-thyroidism (Thyroid Stimulating Hormone (TSH) outside of the normal range) or history of uncontrolled thyroid disorder. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable.
- Hematocrit, white blood cell count or platelets significantly outside the normal reference range.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Morning ExerciseAlso: AM Exercise, AM-EXMorning Exercise will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 6 and 10 AM. | Behavioural | Morning Exercise (AM) |
| Evening ExerciseAlso: PM Exercise, PM-EXPM will be instructed to perform 2000 kcal/wk of moderate to vigorous intensity aerobic exercise between the hours of 3 and 7 PM. | Behavioural | Evening Exercise (PM) |
Primary outcome
Weight Change (kg)
Time frame: Baseline (0) - 13 Months
Body weight will be measured using a digital scale at baseline, 3.5, 7, and 13 months. The primary outcome will be change in weight from baseline to 7 months.
9 secondary outcomes
Fat Mass
Time frame: Baseline (0) - 13 Months
Lean Mass
Time frame: Baseline (0) - 13 Months
Energy Intake
Time frame: Baseline (0) - 7 Months
Total Daily Energy Expenditure
Time frame: Baseline (0) - 7 Months
Hunger and Satiety
Time frame: Baseline (0) - 13 Months
Food Cravings
Time frame: Baseline (0) - 13 Months
Aspects of Eating Behavior
Time frame: Baseline (0) - 13 Months
Non-Exercise Physical Activity (NEPA)
Time frame: Baseline (0) - 13 Months
Sedentary Time
Time frame: Baseline (0) - 13 Months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Overweight and Obesity
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Active, not recruitingPhase 1
A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight
Healthy Volunteers, Overweight or Obesity
Active, not recruitingPhase 2
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
Overweight, Obesity
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Obesity, Overweight and/or Obesity
Active, not recruitingPhase 3
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
Obesity & Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Vicki Catenacci principal investigator
University of Colorado, Denver
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Morning Exercise and Evening Exercise in people with Overweight and Obesity, run by University of Colorado, Denver at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 20 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weight Change (kg) (time frame: Baseline (0) - 13 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026; AzTrials last refreshed its copy on 6 Nov 2026.